Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Coldstream Capital Management Inc.

Coldstream Capital Management Inc. trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 27.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 3,229 shares of the life sciences company’s stock after selling 1,216 shares during the period. Coldstream Capital Management Inc.’s holdings in Illumina were worth $425,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ILMN. Geode Capital Management LLC increased its stake in Illumina by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after acquiring an additional 48,018 shares during the last quarter. Vestcor Inc increased its position in Illumina by 300.7% during the 3rd quarter. Vestcor Inc now owns 12,793 shares of the life sciences company’s stock worth $1,668,000 after purchasing an additional 9,600 shares in the last quarter. M&T Bank Corp raised its holdings in Illumina by 3.4% in the third quarter. M&T Bank Corp now owns 54,378 shares of the life sciences company’s stock valued at $7,091,000 after buying an additional 1,769 shares during the period. LRI Investments LLC lifted its position in Illumina by 284.9% during the third quarter. LRI Investments LLC now owns 535 shares of the life sciences company’s stock valued at $76,000 after buying an additional 396 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. grew its stake in Illumina by 8.8% during the third quarter. Nomura Asset Management Co. Ltd. now owns 50,593 shares of the life sciences company’s stock worth $6,598,000 after buying an additional 4,077 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Morgan Stanley restated an “equal weight” rating and set a $156.00 price objective on shares of Illumina in a research note on Tuesday, November 12th. Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and lowered their target price for the company from $190.00 to $165.00 in a research note on Wednesday. TD Cowen boosted their price target on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, Canaccord Genuity Group increased their price objective on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research report on Tuesday, November 5th. Nine analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $165.95.

Illumina Stock Performance

Shares of ILMN stock opened at $143.87 on Friday. The stock has a market capitalization of $22.82 billion, a price-to-earnings ratio of -14.44 and a beta of 1.11. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66. The company’s 50-day simple moving average is $144.27 and its 200-day simple moving average is $128.44. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. The business’s revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.33 EPS. Equities analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.